利妥昔单抗用于难治性抗3-羟基-3-甲基戊二酰辅酶A还原酶免疫介导的坏死性肌病：一例报告。
Rituximab use for refractory anti-HMGCR immune-mediated necrotizing myopathy: A case report.
作者信息
Gupta Sonia, Rakhra Amandeep, Thallapally Vinay, Nahas Joseph
机构信息
Department of Internal Medicine, Creighton University, Omaha, Nebraska, USA.
Department of Rheumatology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.
出版信息
Intractable Rare Dis Res. 2021 May;10(2):122-125. doi: 10.5582/irdr.2020.03144.
Abstract
Immunosuppression is the cornerstone therapy for anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) myopathy. Typical immunosuppressants such as corticosteroids, methotrexate, and azathioprine have been used in conjunction with removal of the offending agent, yet the use of rituximab is more limited in this type of myopathy. Reported here is a case of a patient who responded well to rituximab (RTX) after the standard immunosuppressants had failed. This case illustrates the importance of further studies to evaluate the role of RTX in anti-HMGCR myopathy.
摘要
免疫抑制是抗3-羟基-3-甲基戊二酰辅酶A还原酶（抗HMGCR）肌病的基石疗法。典型的免疫抑制剂，如皮质类固醇、甲氨蝶呤和硫唑嘌呤，已与去除致病因素联合使用，但利妥昔单抗在这类肌病中的应用更为有限。本文报告了1例患者，在标准免疫抑制剂治疗失败后，对利妥昔单抗（RTX）反应良好。该病例说明了进一步研究以评估RTX在抗HMGCR肌病中作用的重要性。
相似文献
1
Rituximab use for refractory anti-HMGCR immune-mediated necrotizing myopathy: A case report.
Intractable Rare Dis Res. 2021 May;10(2):122-125. doi: 10.5582/irdr.2020.03144.
2
Rituximab in the Treatment of Refractory Anti-HMGCR Immune-mediated Necrotizing Myopathy.
J Rheumatol. 2019 Jun;46(6):623-627. doi: 10.3899/jrheum.171495. Epub 2018 Dec 15.
3
A Child with Refractory and Relapsing Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Myopathy: Case-Based Review.
J Neuromuscul Dis. 2023;10(2):279-291. doi: 10.3233/JND-221557.
4
Pediatric necrotizing myopathy associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies.
Rheumatology (Oxford). 2017 Feb;56(2):287-293. doi: 10.1093/rheumatology/kew386. Epub 2016 Nov 6.
5
Rituximab in the treatment of immune-mediated necrotizing myopathy: a review of case reports and case series.
Ther Adv Neurol Disord. 2021 Mar 12;14:1756286421998918. doi: 10.1177/1756286421998918. eCollection 2021.
6
Statin-associated anti-HMGCR immune-mediated necrotizing myopathy with dermatomyositis-like features: A case report.
SAGE Open Med Case Rep. 2020 Dec 29;8:2050313X20984120. doi: 10.1177/2050313X20984120. eCollection 2020.
7
Initial seronegative immune-mediated necrotising myopathy with subsequent anti-HMGCR antibody development and response to rituximab: case report.
BMC Rheumatol. 2020 Jun 30;4:29. doi: 10.1186/s41927-020-00128-5. eCollection 2020.
8
Treatment experience of Taiwanese patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase myopathy.
Kaohsiung J Med Sci. 2020 Aug;36(8):649-655. doi: 10.1002/kjm2.12240. Epub 2020 Jul 14.
9
Diffuse Large B-cell Lymphoma Complicated with Anti-3-hydroxy-3-methylglutaryl-Coenzyme A Reductase Immune-mediated Necrotizing Myopathy.
Intern Med. 2025 Feb 15;64(4):589-595. doi: 10.2169/internalmedicine.3880-24. Epub 2024 Jul 11.
10
A Rare Case of Anti-HMGCR and Anti-SRP-Positive Immune-Mediated Necrotizing Myopathy.
Qatar Med J. 2022 Feb 22;2022(1):6. doi: 10.5339/qmj.2022.6. eCollection 2022.
引用本文的文献
1
Rituximab in the treatment of anti-HMGCR immune-mediated necrotizing myopathy: Two cases successfully treated.
Rheumatol Immunol Res. 2025 Jul 1;6(2):110-113. doi: 10.1515/rir-2025-0014. eCollection 2025 Jun.
2
Refractory Severe Anti-SRP Myopathy that Improved with Long-term Rehabilitation Therapy: A Case Report.
Prog Rehabil Med. 2025 Jan 22;10:20250003. doi: 10.2490/prm.20250003. eCollection 2025.
3
Six Years Follow-Up of an 11-Year-Old Girl with Anti-HMGCR Myopathy.
J Neuromuscul Dis. 2024;11(4):883-887. doi: 10.3233/JND-240022.
4
Refractory Statin-Induced Immune-Mediated Necrotizing Myositis: Challenges and Perils in Its Management.
Cureus. 2022 May 6;14(5):e24778. doi: 10.7759/cureus.24778. eCollection 2022 May.
本文引用的文献
1
Anti-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) antibody in necrotizing myopathy: treatment outcomes, cancer risk, and role of autoantibody level.
Scand J Rheumatol. 2020 Sep;49(5):405-411. doi: 10.1080/03009742.2019.1672782. Epub 2019 Dec 5.
2
Rituximab in the Treatment of Refractory Anti-HMGCR Immune-mediated Necrotizing Myopathy.
J Rheumatol. 2019 Jun;46(6):623-627. doi: 10.3899/jrheum.171495. Epub 2018 Dec 15.
3
A Case of Atorvastatin-Associated Necrotizing Autoimmune Myopathy, Mimicking Idiopathic Polymyositis.
Case Rep Rheumatol. 2018 Jun 20;2018:5931046. doi: 10.1155/2018/5931046. eCollection 2018.
4
Statin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations.
Expert Rev Clin Immunol. 2018 Mar;14(3):215-224. doi: 10.1080/1744666X.2018.1440206. Epub 2018 Feb 23.
5
224th ENMC International Workshop:: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016.
Neuromuscul Disord. 2018 Jan;28(1):87-99. doi: 10.1016/j.nmd.2017.09.016. Epub 2017 Oct 23.
6
Necrotizing Autoimmune Myopathy: A Rare Variant of Idiopathic Inflammatory Myopathies.
J Investig Med High Impact Case Rep. 2017 Jun 14;5(2):2324709617709031. doi: 10.1177/2324709617709031. eCollection 2017 Apr-Jun.
7
More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy.
Rheumatology (Oxford). 2017 May 1;56(5):787-794. doi: 10.1093/rheumatology/kew470.
8
Treatment and outcomes in necrotising autoimmune myopathy: An Australian perspective.
Neuromuscul Disord. 2016 Nov;26(11):734-740. doi: 10.1016/j.nmd.2016.08.013. Epub 2016 Sep 3.
9
Clinical course and treatment of anti-HMGCR antibody-associated necrotizing autoimmune myopathy.
Neurol Neuroimmunol Neuroinflamm. 2015 Apr 2;2(3):e96. doi: 10.1212/NXI.0000000000000096. eCollection 2015 Jun.
10
An Unusual Case of Statin-Induced Myopathy: Anti-HMGCoA Necrotizing Autoimmune Myopathy.
J Gen Intern Med. 2015 Dec;30(12):1879-83. doi: 10.1007/s11606-015-3303-9. Epub 2015 Apr 9.
Zotero 插件